Glaucoma Subspecialty Day 2018

    The emergence of neuroprotection in glaucoma has led to a need for new measures of treatment efficacy. The identification of in vivo apoptosis could serve as a potential biomarker of disease activity. The technology that has been developed to detect apoptosing retinal cells (DARC) has recently moved from experimental preclinical stages to clinical trials.